Investigational drug · Phase 2
H001
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Circulatory Disease.
Phase 2Last checked: Nov 19, 2026Latest source record: May 9, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
5
Any phase or sponsor naming "H001"
First trial start
2025
Jan 20, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "H001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Circulatory Disease
Largest trials
Live from ClinicalTrials.gov: studies naming "H001" as an intervention, largest first.
- Phase II Clinical Study of H001 Capsule in the Prevention of Venous Thromboembolism After Total Knee ArthroplastyPivotal-lookingRecruiting
Livzon Pharmaceutical Group Inc.Industry
NCT06963320 · 320 participants (planned) · Start Jan 20, 2025 · Primary completion Jun 30, 2025
Drug: H001 Capsule 200mg-qd; Enoxaparin Sodium Injection and 2 more · For: Circulatory Disease
Sites: Shanghai, China
- Proximod Pharmacokinetics In Healthy SubjectsPivotal-lookingCompleted
Longevity Inc.Industry
NCT06361186 · 134 participants · Start Sep 14, 2017 · Primary completion Nov 1, 2017
Drug: Proximod; Placebo · For: Rheumatoid Arthritis
Sites: Changchun, China
- A Study to Evaluate MTM-H-001 Injection in Adult Patients With B-Cell-Related Autoimmune DiseasesNot yet recruiting
Beijing GoBroad HospitalAcademic, hospital or other
NCT07593911 · 75 participants (planned) · Start Jun 2026 · Primary completion Nov 2030
Drug: MTM-H-001 Injection · For: Systemic Lupus Erthematosus (SLE); Lupus Nephritis (LN); Multiple Sclerosis and 3 more
Sites: Beijing, China
- A Study to Evaluate MTM-H-001 Injection in Adult Participants With Relapsed or Refractory B-cell MalignanciesNot yet recruiting
Cancer Institute and Hospital, Chinese Academy of Medical SciencesAcademic, hospital or other
NCT07476378 · 69 participants (planned) · Start Mar 2026 · Primary completion Jan 2028
Drug: MTM-H-001 Injection · For: Lymphoma, Large B-Cell, Diffuse (DLBCL); Lymphoma, Follicular; Lymphoma, Mantle-Cell and 3 more
Sites: Langfang, China
Longevity Inc.Industry
NCT06361199 · 22 participants · Start Dec 16, 2021 · Primary completion Feb 16, 2022
Drug: Proximod; Placebo · For: Rheumatoid Arthritis
Sites: Changchun, China
Newest research
PubMed records naming it or its code names, newest first.
- Genome-wide association mapping and haplotype analysis reveal the genetic architecture of sodicity tolerance in bread wheat (Triticum aestivum L.).
Kumar A, Sathishkumar R, Kant C, et al. · Sci Rep 2026
- Haplotype Variation of TBXT Enhancer Contributes to Tail Length Diversity of Sheep Through Modulation of Gene Expression.
Li JP, Li ZH, Liu CX, et al. · Anim Genet 2026
- Genomic dissection of iron toxicity tolerance in rice identifies key loci, candidate genes, and associated haplotypes.
Jaiswal S, Kumar K, Kumari A, et al. · Sci Rep 2026
- Genome-wide association study (GWAS) and transcription analysis of candidate genes for rice grain eating and cooking quality (ECQ) traits.
Farzad Amirebrahimi F, Saidi A, Ahmadikhah A · BMC Genomics 2025
- Comprehensive Analysis of the TaABCB Gene Family and the Role of TaABCB7 in the Phosphate Starvation Response in Wheat.
Cui G, Wang H, Wang Y, et al. · Biology (Basel) 2025
- Identification of superior haplotypes for flowering time in pigeonpea through candidate gene-based association study of a diverse minicore collection.
Kumar K, Kumari A, Durgesh K, et al. · Plant Cell Rep 2024
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.